<DOC>
	<DOCNO>NCT00599911</DOCNO>
	<brief_summary>The primary purpose study assess efficacy treat patient Major Depressive Disorder one dose Lu AA24530 relative placebo</brief_summary>
	<brief_title>Dose-finding Study With Lu AA24530 Major Depressive Disorder</brief_title>
	<detailed_description>According World Health Organisation , Major Depressive Disorder lead cause disability 4th lead contributor global burden disease . There unmet medical need treatment depressive disorder term insufficient effectiveness unpleasant side-effects current therapy . The overall prognosis disorder positive majority patient , many 30 % patient develop chronic treatment-resistant depression . In study , patient depression treat 6 week . Assessments efficacy safety take place every week first 4 week 6 week treatment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Major Depressive Episode last least 3 month Moderate severe depression Any current psychiatric disorder establish principal diagnosis MDD define DSMIVTR assess MiniInternational Neuropsychiatric Interview ( MINI ) Current past history : manic hypomanic episode , schizophrenia psychotic disorder , include major depression psychotic feature , mental retardation , organic mental disorder , mental disorder due general medical condition define DSMIVTR Major Depressive Episode unresponsive two adequate course antidepressant treatment , least 6 week duration Electroconvulsive therapy within 6 month prior Baseline Ongoing formal cognitive behavioural therapy , systematic psychotherapy , plan initiate therapy study Clinically significant unstable illness , example , hepatic renal insufficiency , cardiovascular , pulmonary , gastrointestinal , endocrine , neurological , infectious , neoplastic , metabolic disturbance The patient pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Drug therapy</keyword>
	<keyword>Depressive disorder</keyword>
	<keyword>Antidepressive agent</keyword>
	<keyword>Depressive symptom</keyword>
	<keyword>Affective disorder</keyword>
	<keyword>Randomized control trial</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Active reference</keyword>
	<keyword>Multicenter study</keyword>
</DOC>